Archive for ‘Urological Instruments’

Page 1 of 212

Flexible Patch with Stainless Steel Microneedles for Safe and Painless Delivery of Drugs

Flexible Patch with Stainless Steel Microneedles for Safe and Painless Delivery of Drugs

patch-patch

 

Scientists at the KTH Royal Institute of Technology in Stockholm, Sweden have developed a new flexible microneedle patch that resolves some of the limitations of similar existing devices. Typically, drug delivery patches designed to penetrate only the top layers of skin, as opposed to transdermal devices, are made of a single material. While it’s best to have the base rather soft to achieve optimal contact and comfort, the needles have to be rigid in order to successfully pierce the skin.

flexible-patchThe KTH  team developed a composite device that consists of a soft base made from a polymer and rigid stainless needles that penetrate the skin. “To the best of our knowledge, flexible and stretchable patches with arrays of sharp and stiff microneedles have not been demonstrated to date,” said Frank Niklaus, a professor of micro and nanofabrication at KTH, in a statement.

The team built two versions of their patch, one more flexible than the other. The more stretchable device showed excellent pliability and each of its 50 needles successfully penetrated the skin in a 30 minute test.

If the technology proves itself in additional studies, it may help make microneedle patches considerably more common and applicable to a variety of patients and conditions.

Study in PLOS ONEFlexible and Stretchable Microneedle Patches with Integrated Rigid Stainless Steel Microneedles for Transdermal Biointerfacing…

Via: KTH Royal Institute of Technology…

Full story

Opioids Market to Approach US$ 42,158.8 Million by 2021

The global opioids market is anticipated to exhibit a stable CAGR during the forecast period (2015-2021).

By product type, the global opioids market is segmented into morphine, codeine, fentanyl, meperidine and methadone. Morphine segment was the largest contributor in overall opioids market, accounting for around 36% share in 2014. However, fentanyl segment is expected to register fastest CAGR of 4.7% during the forecast period. Synthetic opioids such as fentanyl, meperidine and methadone have lucrative growth opportunities in opioids market, owing to their potential application in opioid substitution treatment and fewer side effects as compared to natural opioids. By application, the global opioids market is segmented into analgesia, cough suppression, and diarrhea suppression. Analgesia segment comprises numerous conditions namely, anesthesia, surgical pain, injury or trauma, cancer pain and pain arising from diseases. The analgesia segment accounted for around 67% share in overall opioids market in 2014 and is expected to register fastest CAGR of 3.3% during the forecast period.

Global opioids market growth is mainly driven by increasing demand for opioids in non-cancer pain management, rising geriatric populations suffering from terminal conditions, uncontrolled prescription of opioids especially in North America, and increasing healthcare expenditure for post-surgical care. Moreover, increasing the incidence of trauma injuries, raising awareness about palliative care, higher efficacy of synthetic opioids and favorable reimbursement policies for post-operative care are fueling the growth of opioids market, globally. However, chronic side effects associated with long-term consumption, limited availability of opioids in Asia Pacific, Africa and certain countries in Europe, high level of abusive consumption and growing adoption for pain-free surgeries are likely to impede the growth of global opioids market to a certain extent. Also, the over-regulated environment for the commercial use of opioids especially in developing countries such as India and China and lack of awareness for palliative care in these countries is projected to hamper the growth of the opioids market to a large extent.

North America and Europe have been estimated to collectively account for over 85% revenue share of the total opioids market in 2015. Asia-Pacific is projected to be the fastest-growing market, owing to increasing awareness for cancer pain management, a presence of large patient pool suffering from terminal conditions and reformed regulatory guidelines for the prescription of opioids.

Global opioids market report begins with an overview of the global opioids market in terms of value. This section includes the detailed analysis of key trends, drivers and restraints, and opportunities, which are the main factors impelling growth of the opioids market. Impact analysis of key growth drivers and restraints based on the weighted average of each one of these factors in model-based approach is included in the opioids market report. The report provides a scrutinized information on the potential scope of Abuse Deterrent Formulations (ADF) with the help of pipeline analysis to better equip clients with crystal clear decision-making insights.

Request to view Table of Content @ http://www.persistencemarketresearch.com/market-research/opioids-market/toc

Key players operating in the global opioid market include Pfizer Inc., Purdue Pharma, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Actavis Plc., Sanofi, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc. and Egalet. Companies are majorly focusing on the development of abuse-deterrent formulations, owing to increased abusive consumption of opioids. Companies are also collaborating with local manufacturers to gain maximum market share from their generic products.

To Buy Full Report for a Single User @ http://www.persistencemarketresearch.com/checkout/3066

About Us

Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States

USA – Canada Toll Free: +1 800-961-0353

Email: sales@persistencemarketresearch.com

media@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Full story

Ostomy Care Accessories Market Worth US$ 503.7 Million by 2021

Ostomy Care Accessories Market Worth US$ 503.7 Million by 2021

doct

 

The ostomy care accessories market has been estimated to be valued at US$ 347.2 Mn by the end of 2015, and is expected to expand at a CAGR of 6.8% during the forecast period (2015-2021) to account for US$ 503.7 Mn by 2021.

Ostomy care accessories are designed to enhance performance and comfort of an ostomy pouching system. There are various types of ostomy care accessories such as skin protection & skin barriers, belt, tapes and adhesives, irrigation sets & sleeves, convex inserts and stoma caps. Irrigation sets and sleeves may be used by some colostomies to reduce or eliminate the need to constantly wear a colostomy bag by cleaning stool directly out of the colon through the stoma. Stoma capes are small sized plastic cups or closed pouches that are worn for a short period of time for occasions such as swimming, playing sports, or during intimate moments where patient do not want to wear ostomy pouch as these are big in size and have high visibility. Stoma capes can also be used after irrigation when output has become predictable.

Ostomy care accessories market is growing mainly driven by increasing number of ostomates, technological advancement, and product innovation, and increasing the incidence of gastrointestinal disease. Also, rising awareness about ostomy care accessories available in the market and growing aging population are fuelling the growth of ostomy care accessories market globally. Ostomy care accessories find various applications such as sealing, cleaning, drainage, and lubrication. Stoma sealing helps reduce the risk of leakage. The cleansing application includes accessories that protect the skin and gently clean the stoma. Drainage application includes accessories such as irrigation sets and sleeves that are used by the colostomies who do not want to wear colostomy bag by cleaning stool directly out of the colon through the stoma. Lubrication is the ostomy care application that helps ensure that the content is always at the bottom of the bag and not around your stoma. Ostomy care accessories are used by various end users such as hospitals, ambulatory surgical centers, and home care settings.

Rising number of campaigns to raise awareness about ostomy is a major factor expected to further drive overall growth of the ostomy care accessories market over the forecast period. However, lack of awareness in developing countries, increasing pricing pressure and unfavorable reimbursement scenario in certain developed countries are some of the major factors that restrict the growth of the market.

Increasing partnerships between manufacturers and distributors, growing market share of domestic players, increasing sales through alternative/non-conventional channels such as the Internet, reducing operating cost by moving production to countries with low labor costs, extensive R&D activities, and increasing adoption of alcohol-free ostomy accessories are some of the trends observed in the global ostomy care accessories market.

By region, Europe has been estimated to dominate the ostomy care accessories market with over 42.1% share by 2015 end and is expected to remain dominant throughout the forecast period. Skin protection and skin barriers are the largest segment in global ostomy care accessories market. The global skin protection and skin barriers segment are expected to increase at a CAGR of 6.6% in terms of value during the forecast period. Belt, tapes and adhesives are the second-largest segment in the global ostomy care accessories market and is expected to expand at a CAGR of 6.8% in terms of value during the forecast period.

Asia-Pacific represents the most lucrative market, followed by North America for ostomy care accessories This is primarily due to increase awareness about ostomy care accessories available in the market, growing operational activities by key players and rising demand for better healthcare facilities in India, China, Bangladesh, Philippines and Indonesia. Asia Pacific has been estimated to account for 15.1% market share in the global ostomy care accessories market in 2015, which is expected to increase to 15.6% market share by 2021.

Request to view Table of Content @ http://www.persistencemarketresearch.com/market-research/ostomy-care-accessories-market/toc

Key market players covered in this report are Coloplast Corp., ConvaTec Inc., Hollister Inc., EuroMed Inc., 3M, Smith & Nephew, FNC Medical, Nu-Hope Laboratories, Inc., Marlen Manufacturing & Development Torbot Group Inc and Cymed Ostomy Co. These players have been profiled on the basis of various attributes such as company overview, recent developments, growth strategies, SWOT analysis and sustainability.

To Buy Full Report for a Single User @ http://www.persistencemarketresearch.com/checkout/3200

The ostomy care accessories market is segmented as follows:

By Product Type:

  • Belts, Tapes, Adhesives
  • Skin Protection and Skin Barriers
  • Irrigation Sets & Sleeves
  • Convex Inserts
  • Stoma Caps

By Application Type:

  • Sealing
  • Cleansing
  • Lubrication
  • Drainage

By End User:

  • Hospital
  • Ambulatory Surgical Centers
  • Home Care Settings

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East & Africa

About Us

Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States

USA – Canada Toll Free: +1 800-961-0353

Email: sales@persistencemarketresearch.com

media@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Full story

Cambridge Medical Robotics Shows Off Its New Versius System

Cambridge Medical Robotics Shows Off Its New Versius System

versius

 

Cambridge Medical Robotics, a UK firm, is revealing its Versius robotic surgery system. The system consists of modular robotic arms, any number of which can be used depending on a procedure. The arms can have a camera or any one of the dozen or so tools attached, and they can be quickly swapped for other tools as necessary.

Each of the arms can be placed around the patient table or even hung from above to save valuable space. The surgeon wears a pair of 3D glasses and operates by looking at a monitor instead of peering into a scope common on existing systems. This can help improve ergonomics and allow the surgeon to see and interact easier with clinicians managing the patient and the robot. The robot is operated using a controller similar to video game joysticks and the system delivers haptic feedback from the instrument to the controller, so the surgeon can actually feel the anatomy being worked on.

Unlike existing robotic surgical systems, the Versius can work with instruments requiring only a 5 mm incision. Typically the smallest instrument sizes on robotic systems is 8 mm, and unlike 5 mm incisions these typically require suturing and maintenance.

The company has already performed a number of studies, including on cadavers, and is compiling responses and data from 32 surgeons that has already used the Versius system. The firm hopes to receive the CE Mark in Europe in 2018 and FDA regulatory green light shortly thereafter.

More info from CMR…

Full story

MIT Scientists Unveil Radiation-free MRI Brain Imaging Tracer

MIT Scientists Unveil Radiation-free MRI Brain Imaging Tracer

Fig2_injections_v9b

 

Existing methods of spotting the presence of specific molecules in the brain requires using chemical or radioactive markers. These can have side effects for patients, at times be difficult to acquire and use, and they’re limited in their spatial and temporal resolutions. Now scientists at MIT have come up with an entirely new method of imaging molecules that uses targeted proteins and MRI to get a quality picture of activity inside the brain.

The proteins were designed to hold onto a peptide called calcitonin gene-related peptide (CGRP). CGRP is involved in migraines and inflammation, dilating blood vessels as it passes through. The protein/peptide packages are designed to open up when in the presence of proteases, the target molecules the researchers were looking for, and release the CGRP. Since the peptide is released wherever the proteases are present, nearby vessels begin to dilate. This change in blood flow can be spotted using MRI, revealing the location of the target protease molecules.

The same technique is now being translated to target neurotransmitters like dopamine and serotonin. This will require engineering new protein structures that hold onto CGRP and break down when a specific neurotransmitter is present.

From the study abstract in Nature Communications:

Variants of the calcitonin gene-related peptide artificially activate vasodilation pathways in rat brain and induce contrast changes that are readily measured by optical and magnetic resonance imaging. CGRP-based agents induce effects at nanomolar concentrations in deep tissue and can be engineered into switchable analyte-dependent forms and genetically encoded reporters suitable for molecular imaging or cell tracking. Such artificially engineered physiological changes, therefore, provide a highly versatile means for sensitive analysis of molecular events in living organisms.

Open access study in Nature Communications: Molecular imaging with engineered physiology…

Via: MIT…

Full story

The Coming Future of Surgical Robotics: Interview with CEO of TransEnterix

The Coming Future of Surgical Robotics: Interview with CEO of TransEnterix

transenterix

 

TransEnterix is a late stage surgical robotics company founded in 2006. The company is dedicated to improving clinical outcomes through the use of robotics in surgery. TransEnterix acquired the surgical robotics division of SOFAR S.p.A in 2015 which included the TELELAP ALF-X advanced robotic system. TransEnterix is now focusing on commercialization of this platform as the Senhance robotic system. We had the opportunity to sit down with the CEO of TransEnterix, Todd Pope, to discuss the future of surgical robotics and positioning of the Senhance system in the market.

William Kethman, MD, Medgadget: Can you tell us about TransEnterix and what you see as the future of robotic surgery?

todd-pope-transenterixTodd Pope, TransEnterix: TransEnterix is focused on the development of surgical robotics to improve the performance and lessen the invasiveness of surgery. We seek to enhance the capabilities of surgeons by providing a sense of touch, improved visual control, superior ergonomics, and precision during complex surgery using small instruments that require minimal incisions. We believe that the role of robotic assistance in surgery has just begun, with many more procedures benefiting from this new technology and a growing accessibility to surgeons and patients alike.

 

Medgadget: What differentiates the Senhance system in the market?

Pope: Surgeons can use the Senhance for a wide range of general surgery, urology, thoracic and gynecologic conditions that are both cancer-related and benign.

Additionally, the Senhance is unique in the sense that it offers advanced features that no other approved robot on the market is offering. The Senhance is the first system in clinical use that brings haptic force feedback to robotic surgery. This feature enables the surgeon to feel the level of force applied during delicate tasks. The Senhance also enhances visual control with an innovative eye-sensing system that allows the surgeon to seamlessly control their vision by simply moving their eyes during a robotic surgery procedure, allowing them to operate without having to stop using their instruments in order to move a camera. This is a significant game changer, especially when considering the level of precision required during surgery. The Senhance also offer wristed instrumentation that helps surgeons maneuver instrument tips in tight spaces.

The system is also unique in that it minimizes disruption by allowing surgeons to utilize the hospital’s existing investments in operating room beds, sterilization equipment, and trocars and is specifically designed to perform multi-quadrant surgeries. This means that hospitals can use The Senhance at a cost that is similar to current manual laparoscopy. In an era of continued pressure on operational costs, The Senhance can greatly increase the cost-benefit equation of adding robotic assistance.

 

Medgadget: What are you plans for FDA clearance of The Senhance for use in the US?

Pope: We are already cleared via CE Mark, and we are working diligently to submit The Senhance to the FDA for use in the United States. In early June, we submitted The Senhance’s pre-submission to the FDA. The CE Mark is accepted in over 40 counties and gives us a wide geography to build out our initial footprint of Senhance users.

 

Medgadget: Can you speak in more detail about the economic drivers behind the use of Senhance?

Pope: Currently, robotic surgery does not have its own reimbursement codes. In many countries, the patient must pay out of pocket if a robotic system is used. This leads to the vast majority of the robotic procedures done today to be in the United States. There is so much value that can be added by robotic assistance, but the impact is being severely limited by high per procedure costs. That’s why Senhance is designed to keep the actual operating costs low by using fully reusable instruments, just like most laparoscopic procedures. The future growth of robotics will need to come from converting procedures from manual laparoscopy to robotically enhanced laparoscopy. Operative costs must be close to traditional laparoscopy in order for much of this transition to occur.

 

Medgadget: Can you tell us about the experiences that clinicians and patients have had with the system? What are some of the benefits that these stakeholders experience?

Pope: Senhance improves the entire surgical experience for the patient. The precision and minimal invasiveness means that the patient can recover more quickly vs. open surgery or procedures that use larger diameter trocars. Larger incisions potentially increase the risk of infection and blood loss, incisional hernias, or longer hospital stays, which inevitably drives up the cost of the surgery.

Clinicians are particularly benefiting from the presence of haptic force feedback for the first time, with physical touch and ability to feel is vital in open and laparoscopic surgery. Surgeons have also commented that Senhance’s eye-tracking capabilities are a significant advantage over other robotic systems.

Many clinicians have also appreciated the way our system builds on the fundamentals of laparoscopy to allow them to quickly adopt to our technology with low learning curves.

Senhance has just begun being utilized and we will see clinical and patient experiences expand with more and different procedures. We are very encouraged by the quality of surgical experience as has been documented and reported thus far and excited for the future.

Full story

Movation Total Knee Arthroplasty System from DJO

Movation Total Knee Arthroplasty System from DJO

Movation Total Knee Arthroplasty System from DJO

SAN DIEGO, CA, September 18, 2012 – DJO Global, Inc. (“DJO” or the “Company”), a leading provider of medical device solutions for musculoskeletal health, vascular health and pain management, announced that the first Movation™ Total Knee Arthroplasty (TKA) was implanted on Tuesday, September 4, 2012. The Movation Knee stems from a long tradition of Hospital for Special Surgery (HSS) excellence, complemented by a complete instrumentation system designed with simplicity and efficiency in mind.

The Movation Posterior Stabilized (PS, used in posterior cruciate ligament deficient knees) Knee design is licensed from the Hospital for Special Surgery (HSS) in New York, NY. HSS prides itself in being the largest joint replacement institution in the country, and also has earned an outstanding reputation for high quality engineering. DJO Surgical licensed this patent for a classic PS Knee solution, and re-defined it with modern innovative features, including a constant axis femoral component, contoured insert condyles for reduced rotational stress, reduced and rounded trochlear transition, and anatomic femoral and baseplate components.

Movation merges decades of successful clinical PS knee history with modern active patient requirements. “Patients needing a knee replacement are approaching surgeons with more demanding activity requirements,” said Bryan Monroe, Senior Vice President and General Manager of DJO Surgical. “Our goal was to develop a knee system with features that we know have historically performed extremely well, but also incorporate assets that allow TKA patients to remain active, such as high flexion allowance, enhanced stability through flexion, and e-plus™ vitamin E polyethylene.”

Instrumentation to implant the Movation Knee was a key focus of the design team. Reducing the overall quantity of instruments and making the instrument flow efficient can contribute to a reduced surgery time, which benefits the patient, the surgeon, and the hospital. Simple quick connect handles, color coded buttons, and magnetic attachments contribute to the smooth flow and reliability of the procedure.

Dr. Barry Waldman, co-designer of the Movation Knee and Orthopedic Surgeon at Sinai Hospital in Baltimore, MD, stated “Our team was very excited to perform our first Movation TKA. This timeless PS knee solution combines easy to use instrumentation with upgraded PS Knee features that I believe will give our patients more stability and deeper flexion than we could obtain in the past. I am looking forward to seeing more of our patients benefit from this new innovation.”

The Movation System will be fully launched at AAOS 2013, and will include e-plus blended vitamin E polyethylene which provides long-term wear benefits to TKA patients.

About DJO Global

DJO Global is a leading global developer, manufacturer and distributor of high-quality medical devices that provide solutions for musculoskeletal health, vascular health and pain management. The Company’s products address the continuum of patient care from injury prevention to rehabilitation after surgery, injury or from degenerative disease, enabling people to regain or maintain their natural motion. Its products are used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, Empi®, ProCare®, DJO® Surgical and Dr. Comfort®.

DJO Global has launched the Movation, a total knee arthroplasty (TKA) system developed at the Hospital for Special Surgery in New York City. The company licensed the technology and added a few features of its own to improve comfort and performance.

The system comes with a newly developed instrument set that was designed for easier and more efficient implantation.

More about the Movation from the announcement:

DJO Surgical licensed this patent for a classic PS Knee solution, and re-defined it with modern innovative features, including a constant axis femoral component, contoured insert condyles for reduced rotational stress, reduced and rounded trochlear transition, and anatomic femoral and baseplate components.

Movation merges decades of successful clinical PS knee history with modern active patient requirements. “Patients needing a knee replacement are approaching surgeons with more demanding activity requirements,” said Bryan Monroe, Senior Vice President and General Manager of DJO Surgical. “Our goal was to develop a knee system with features that we know have historically performed extremely well, but also incorporate assets that allow TKA patients to remain active, such as high flexion allowance, enhanced stability through flexion, and e-plus™ vitamin E polyethylene.”

Instrumentation to implant the Movation Knee was a key focus of the design team. Reducing the overall quantity of instruments and making the instrument flow efficient can contribute to a reduced surgery time, which benefits the patient, the surgeon, and the hospital. Simple quick connect handles, color coded buttons, and magnetic attachments contribute to the smooth flow and reliability of the procedure.

Source : http://www.djoglobal.com/investors/press-releases/djo-surgical-business-unit-djo-global-announces-launch-movation-knee-system

Full story

New Microfluidic Chip for Low Cost, Rapid Testing of Influenza Strains

New Microfluidic Chip for Low Cost, Rapid Testing of Influenza Strains

New Microfluidic Chip for Low Cost, Rapid Testing of Influenza Strains

The novel H1N1 flu pandemic in 2009 underscored weaknesses in methods widely used to diagnose the flu, from frequent false negatives to long wait times for results. Now a four-year, National Institutes of Health-funded study of 146 patients with flu-like symptoms spearheaded by Associate Professor Catherine Klapperich (BME, MSE) has validated a prototype rapid, low-cost, accurate, point-of-care device that promises a better standard of care. Once optimized and deployed in the clinic, the new device could provide clinicians with an effective tool to quickly diagnose both seasonal and pandemic strains of influenza, and thus limit the spread of infection.

The study’s research team—Klapperich, Qingqing Cao (ME PhD’11), Madhumita Mahalanabis (BME postdoctoral fellow), Jessie Chang (BME MS’10), Brendan Carey (BME’11), Christopher Hsieh (BME’11) and Ahjegannie Stanley (summer intern) from the College of Engineering; medical personnel from the Boston University Medical Center (BUMC) Emergency Department; and an infectious disease physician from Beth Israel Deaconess Medical Center (BIDMC)/ Harvard Medical School—published its findings in the March 22 online edition of PLoS ONE.

To produce a faster, cheaper, highly accurate flu diagnostic test that could be run at the point of care, the researchers miniaturized an expensive, three-hour, lab-scale diagnostic test—known as RT-PCR and now considered the gold standard in flu detection—into a single-use microfluidic chip. About the size of a standard microscope slide, the integrated chip consists of a column at the top that extracts RNA from signature proteins in the sample associated with the influenza A virus; a middle chamber that converts the RNA into DNA; and a climate-controlled lower channel used to replicate the DNA in sufficient quantities so it can be detected by an external reader.

Working with two types of nasal specimens, the researchers used the chip to produce results that matched the high accuracy and relatively fast turn-around time of the lab-scale method.

“We wanted to show that our technique was feasible on real-world samples prepared on the chip,” said Klapperich. “Making each chip single-use decreases the possibility of cross-contamination between specimens, and the chip’s small size makes it a good candidate for true point-of-care testing.”

The microfluidic chip also proved far more effective than other commonly used flu diagnostic tests including viral culture, a lab procedure requiring up to a week to produce results; rapid immunoassays, which work like pregnancy tests but were only 40 percent reliable in detecting the presence of a flu virus in this study; and direct fluorescent antigen testing (DFA), a more accurate but labor-intensive process in which medical personnel prepare and interpret samples stained with fluorescent antibodies.

“The new test represents a major improvement over viral culture in terms of turn-around time, over rapid immunoassay tests in terms of sensitivity (ability to detect the virus from minimal sample material) and over DFA and RT-PCR in terms of ease of use and portability,” Klapperich observed.

Ultimately seeking to enable clinicians to use their microfluidic chips for frontline flu virus detection, the researchers next plan to optimize their method so that it can produce results in a third less time (an hour) with chips that cost half as much to make (five dollars). In addition, they are exploring ways to develop a lower cost external reader that’s no bigger than a clinical digital thermometer.

A rapid, low cost, accurate point-of-care (POC) device to detect influenza virus is needed for effective treatment and control of both seasonal and pandemic strains. We developed a single-use microfluidic chip that integrates solid phase extraction (SPE) and molecular amplification via a reverse transcription polymerase chain reaction (RT-PCR) to amplify influenza virus type A RNA. We demonstrated the ability of the chip to amplify influenza A RNA in human nasopharyngeal aspirate (NPA) and nasopharyngeal swab (NPS) specimens collected at two clinical sites from 2008–2010. The microfluidic test was dramatically more sensitive than two currently used rapid immunoassays and had high specificity that was essentially equivalent to the rapid assays and direct fluorescent antigen (DFA) testing. We report 96% (CI 89%,99%) sensitivity and 100% (CI 95%,100%) specificity compared to conventional (bench top) RT-PCR based on the testing of n = 146 specimens (positive predictive value = 100%(CI 94%,100%) and negative predictive value = 96%(CI 88%,98%)). These results compare well with DFA performed on samples taken during the same time period (98% (CI 91%,100%) sensitivity and 96%(CI 86%,99%) specificity compared to our gold standard testing). Rapid immunoassay tests on samples taken during the enrollment period were less reliable (49%(CI 38%,61%) sensitivity and 98%(CI 98%,100%) specificity). The microfluidic test extracted and amplified influenza A RNA directly from clinical specimens with viral loads down to 103 copies/ml in 3 h or less. The new test represents a major improvement over viral culture in terms of turn around time, over rapid immunoassay tests in terms of sensitivity, and over bench top RT-PCR and DFA in terms of ease of use and portability.

Researchers from Boston University and Harvard Medical School have been testing a new microfluidic chip that performs nucleic acid extraction and reverse transcription-PCR (RT-PCR) in one device and features easily adjustable thermal and fluidic control.

The team hopes that the new technology will speed up and make more available rapid testing and identification of influenza infections.

More about the chip from Boston University’s announcement:

f84j0fv9jf New Microfluidic Chip for Low Cost, Rapid Testing of Influenza Strains

To produce a faster, cheaper, highly accurate flu diagnostic test that could be run at the point of care, the researchers miniaturized an expensive, three-hour, lab-scale diagnostic test—known as RT-PCR and now considered the gold standard in flu detection—into a single-use microfluidic chip. About the size of a standard microscope slide, the integrated chip consists of a column at the top that extracts RNA from signature proteins in the sample associated with the influenza A virus; a middle chamber that converts the RNA into DNA; and a climate-controlled lower channel used to replicate the DNA in sufficient quantities so it can be detected by an external reader.

Working with two types of nasal specimens, the researchers used the chip to produce results that matched the high accuracy and relatively fast turn-around time of the lab-scale method.

The microfluidic chip also proved far more effective than other commonly used flu diagnostic tests including viral culture, a lab procedure requiring up to a week to produce results; rapid immunoassays, which work like pregnancy tests but were only 40 percent reliable in detecting the presence of a flu virus in this study; and direct fluorescent antigen testing (DFA), a more accurate but labor-intensive process in which medical personnel prepare and interpret samples stained with fluorescent antibodies.

Source : http://www.bu.edu/phpbin/news-cms/news/?dept=666&id=59219

Full story

Toshiba establishes Chinese Procurement Center in Shanghai

Toshiba establishes Chinese Procurement Center in Shanghai

Toshiba Medical Systems Corporation has established the Chinese Procurement Center in Shanghai.

Our procurement bases were previously at our headquarters and in Dalian, China. By opening the Chinese Procurement Center in Shanghai at this time, we have positioned our headquarters as the global procurement control center and established a cooperative procurement system consisting of three procurement bases, including the Toshiba Dalian medical equipment factory, which is our overseas manufacturing subsidiary in China. The objectives are expansion and improved efficiency in global procurement.

Shanghai, where we have established the Chinese Procurement Center, is located in the center of eastern China, which is home to the overseas manufacturing subsidiaries of many American and European medical equipment manufacturers. This region also hosts many factories serving medical component/material manufacturers based in the United States, Europe, and Japan, as well as the manufacturing bases of local medical component/material companies.

At the Chinese Procurement Center, not only procurement staff with experience working in Japan and other countries but also professional staff in the fields of product development, manufacturing technology, and quality control work together to promote procurement activities in China, taking full advantage of the great potential of Chinese component/material manufacturers while maintaining the same level of quality as in Japan. This is the first trial of such an organizational structure in the Toshiba Group.

The Chinese Procurement Center is located in the Procurement Office of Toshiba China Co., Ltd., which is Toshiba Corporation’s overseas subsidiary for regional coordination. We will also strengthen cooperation with sourcing staff in other business divisions of the Toshiba Group to take full advantage of the synergistic effects of the Toshiba Group’s global procurement activities.

In order to address today’s extremely challenging business conditions such as the high yen and sales price erosion, Toshiba Medical Systems Corporation plans to increase its global procurement percentage to 75% by the end of fiscal year 2014, thus reducing manufacturing costs and countering the effects of foreign exchange imbalances.

Source : http://www.news-medical.net/news/20120803/Toshiba-establishes-Chinese-Procurement-Center-in-Shanghai.aspx

Full story

Personal Activity Monitor to Interface with Sprint Phones

Personal Activity Monitor to Interface with Sprint Phones

Personal Activity Monitor to Interface with Sprint Phones

Sprint is partnering with BodyMedia out of Pittsburgh, PA to provide real-time connectivity between BodyMedia’s personal monitoring wristbands and Sprint’s smartphones. s9zng08u Personal Activity Monitor to Interface with Sprint PhonesSimilar to the popular FitBit, BodyMedia’s wristband tracks activity levels which are then stored and analyzed on your phone.

Through the Sprint ID BodyMedia Pack, users will be able to make use of custom Android applications to see their calorie input vs. output, understand their calorie balance and create personalized workouts based upon caloric activity or step targets. The BodyMedia ID pack will be available during first half of 2011 while the new wireless embedded products will be launched this year.

BodyMedia has announced a personalized feedback system called BodyMedia FIT coach, which makes use of analytics software from IBM to give customized weigh loss advice. This will help people better understand how they progress and help them to accomplish their fitness goals.

The FIT coach will analyze user input, historical and current BodyMedia data to provide personal feedback. The BodyMedia FIT Armbands have already tracked a lot of data of many people up until this moment: using all this information to make a personalized advice can improve the success of consumer’s weight loss plans.

The feedback system is based on IBM Decision Management platform. It makes calculations to assess the users’ current status and compare it to the long-term goals. Down below you can find the key features of the FIT coach.

“The new FIT coach component of the BodyMedia FIT Activity Manager software is the first solution of its kind that can calculate and deliver information on:

Whether users are missing, meeting or beating their targets for burning calories daily

Multiple activity options for making up shortfalls in daily goals for burning calories (e.g. “Hop on the treadmill and walk for about one hour at a speed of four mph and you should hit your goal for burning calories today”)

Nutritional analysis of each day’s eating patterns, along with relevant recommendations for correcting problems such as excess fat intake

Overall progress towards the users’ weight loss goals, along with advice to stay on course”

Source : http://medgadget.com/2011/01/personal_activity_monitor_to_interface_with_sprint_phones.html

Related Posts Plugin for WordPress, Blogger...

Full story

Page 1 of 212
Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes